about
Exploiting IL-17-producing CD4+ and CD8+ T cells to improve cancer immunotherapy in the clinicβ-catenin and PI3Kδ inhibition expands precursor Th17 cells with heightened stemness and antitumor activity.Dendritic Cells in Irradiated Mice Trigger the Functional Plasticity and Antitumor Activity of Adoptively Transferred Tc17 Cells via IL12 SignalingToll-like receptor agonist therapy can profoundly augment the antitumor activity of adoptively transferred CD8(+) T cells without host preconditioning.Th17 cells are refractory to senescence and retain robust antitumor activity after long-term ex vivo expansion.Th17 cells in cancer: the ultimate identity crisis.Reducing CD73 expression by IL1β-Programmed Th17 cells improves immunotherapeutic control of tumors.The Basics of Artificial Antigen Presenting Cells in T Cell-Based Cancer ImmunotherapiesPI3Kδ Inhibition Enhances the Antitumor Fitness of Adoptively Transferred CD8+ T CellsHuman CD26high T cells elicit tumor immunity against multiple malignancies via enhanced migration and persistence.Targeted Complement Inhibition Protects Vascularized Composite Allografts From Acute Graft Injury and Prolongs Graft Survival When Combined With Subtherapeutic Cyclosporine A Therapy.When worlds collide: Th17 and Treg cells in cancer and autoimmunity.Gene editing for immune cell therapiesCAR-T cells secreting BiTEs circumvent antigen escape without detectable toxicityChimeric Antigen Receptor T Cells Targeting CD79b Show Efficacy in Lymphoma with or without Cotargeting CD19
P50
Q28075992-360BAD00-A026-4760-A267-6B7FBDCFE225Q33578997-394140C0-AB3C-4C79-B724-3F1703388D97Q35674805-A477BDCE-1C81-4BD4-B121-2DD0D21F9243Q36583710-C034C5D2-7E19-4303-890A-5D40C8299688Q37677403-3259FB35-6913-44E4-8359-63C019033AB6Q38225542-1FB62075-79E8-4265-A298-FF00122B5EEAQ38958004-85783C9D-83A3-4489-91CF-FA1B22816343Q41442041-F78E4C30-DD9D-4AEE-BCE9-6EF0FFAC186CQ42369747-635C62C6-466A-44B8-8182-588FE009CF87Q47094002-E726D17A-4D93-4857-B5EE-BB4F2F35220AQ48001428-FD32B4B3-7092-4D0F-A0D7-D650BCC1DF47Q52689973-2B233E8F-6929-409A-B140-F113E4826B1EQ67201058-278125A4-DE03-4292-9ECD-E4C241C87F64Q92093435-C5248759-3F14-4D95-A482-6D1B8997BFF6Q92794400-FB2F6B80-AD03-44B5-9BFF-0AE234533578
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Stefanie R Bailey
@ast
Stefanie R Bailey
@en
Stefanie R Bailey
@es
Stefanie R Bailey
@nl
type
label
Stefanie R Bailey
@ast
Stefanie R Bailey
@en
Stefanie R Bailey
@es
Stefanie R Bailey
@nl
prefLabel
Stefanie R Bailey
@ast
Stefanie R Bailey
@en
Stefanie R Bailey
@es
Stefanie R Bailey
@nl
P106
P31
P496
0000-0002-1175-521X